Manuals+

Novo Nordisk R&D Investor Event

Chicago, 22 June 2025

A Focused Healthcare Company

Novo Nordisk, a global healthcare company, presented its research and development initiatives with a specific emphasis on diabetes and obesity care. The event provided insights into the company's strategic focus, pipeline advancements, and the latest clinical data supporting its therapeutic solutions.

Key Areas of Focus:

  • Advancements in diabetes treatment, including new guidelines and semaglutide's role.
  • Developments in obesity care, showcasing pipeline assets and unmet needs.
  • Clinical trial results for semaglutide in addressing comorbidities associated with type 2 diabetes, such as cardiovascular and kidney disease.
  • The company's commitment to sustainability and societal value.

Featured Speakers:

  • Karsten Munk Knudsen, Executive Vice President and CFO
  • Martin Holst Lange, Executive Vice President and Head of Development
  • Ludovic Helfgott, Executive Vice President and Head of Product and Portfolio Strategy

Learn More:

For more information on Novo Nordisk's commitment to transforming lives through innovative treatments, please visit Novo Nordisk's official website.

PDF preview unavailable. Download the PDF instead.

novo-nordisk-r-and-d-presentation-20250622 Microsoft PowerPoint for Microsoft 365

Related Documents

Preview Novo Nordisk R&D Investor Event: Diabetes and Obesity Care Focus
Presentation from Novo Nordisk's R&D Investor event held on June 22, 2025, in Chicago. The event highlights the company's focus on diabetes and obesity care, detailing research, clinical trials, and strategic aspirations.
Preview Novo Nordisk Investor Presentation: First Six Months of 2025
An investor presentation from Novo Nordisk detailing their performance and strategic aspirations for the first six months of 2025. The report covers progress on environmental, social, and governance (ESG) goals, commercial execution in diabetes and obesity care, innovation in therapeutic focus, and financial highlights.
Preview Novo Nordisk H1 2025 Financial Report
Novo Nordisk announces strong sales growth in the first half of 2025, with a 16% increase in Danish kroner and 18% at constant exchange rates. The report details performance in Diabetes and Obesity care, Rare disease segments, and financial highlights.
Preview Novo Nordisk Investor Presentation H1 2025: Financials and Strategic Update
Novo Nordisk's investor presentation for the first six months of 2025, detailing financial performance, strategic aspirations, pipeline advancements in diabetes, obesity, rare diseases, and cardiovascular/emerging therapies, alongside market insights and sustainability efforts.
Preview Connecting NovoPen 6 and NovoPen Echo Plus to Your Smartphone
A comprehensive guide on connecting NovoPen 6 and NovoPen Echo Plus insulin pens to Android and iOS smartphones, detailing compatibility, NFC usage, and troubleshooting tips.
Preview Connecting NovoPen 6 and NovoPen Echo Plus to Smartphones
A comprehensive guide for connecting NovoPen 6 and NovoPen Echo Plus insulin pens to Android and iOS smartphones. Learn about NFC requirements, connection tips, and device compatibility.
Preview NovoPen 6 and NovoPen Echo Plus: Your Quick Guide to Insulin Pen Use
A concise, SEO-optimized guide to using Novo Nordisk's NovoPen 6 and NovoPen Echo Plus insulin pens, covering preparation, injection, and dose checking. Includes step-by-step instructions and product specifications.
Preview Novopen 4 SL Insulin Pen Instructions
Comprehensive instructions for using the Novopen 4 SL insulin pen, including assembly, injection, and maintenance. Learn how to safely and effectively administer insulin.